Ligand id: 6591

Name: natalizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: natalizumab

Immunopharmacology Comments
Natalizumab targets α4-containing intergrins, including the α4β1 lymphocyte homing receptor.
Immunopharmacology Disease
Disease X-Refs Comment References
Crohn's disease Disease Ontology: DOID:8778
OMIM: 266600
Orphanet: ORPHA206
Approved drug for CD.
Multiple sclerosis Disease Ontology: DOID:2377
OMIM: 126200
Orphanet: ORPHA802
Approved for the treatment of relapsing forms of multiple sclerosis.